Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4303835 Target Snapshot

SARS-CoV-2 · ORGANISM · Severe acute respiratory syndrome coronavirus 2

11,875Compounds
1,202Assays
142Approved Drugs
12,741.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats SARS-CoV-2 as ChEMBL target CHEMBL4303835. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
SARS-CoV-2
ORGANISM · Severe acute respiratory syndrome coronavirus 2
As of 2026-09-13
ChEMBL target ID
CHEMBL4303835
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether SARS-CoV-2 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSARS-CoV-2
UniProt AccessionN/A

SARS-CoV-2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as SARS-CoV-2.

Review nameSARS-CoV-2
OrganismSevere acute respiratory syndrome coronavirus 2
Clinical Profile

Clinical Phase Distribution

142
Approved
42
Phase III
82
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC5010,338.0
EC502,403.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5557776 9.37 EC50 0.43 Preclinical
CHEMBL5557224 9.28 EC50 0.53 Preclinical
CHEMBL91704 9.17 IC50 0.68 Clinical
CHEMBL451930 9.15 EC50 0.7 Approved
CHEMBL5559530 9.07 EC50 0.86 Preclinical
CHEMBL5205032 9.0 EC50 1.0 Preclinical
CHEMBL5270743 8.96 EC50 1.1 Preclinical
CHEMBL5562461 8.96 EC50 1.1 Preclinical
CHEMBL5195325 8.92 EC50 1.2 Preclinical
CHEMBL5555618 8.92 EC50 1.2 Preclinical
Distribution

pChEMBL Value Distribution

564
5.0
498
5.5
470
6.0
291
6.5
186
7.0
111
7.5
47
8.0
17
8.5
8
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

NIRMATRELVIR
CHEMBL4802135
Approved 2023
REMDESIVIR
CHEMBL4065616
Approved 2020
FEDRATINIB
CHEMBL1287853
Approved 2019
GILTERITINIB
CHEMBL3301622
Approved 2018
PLITIDEPSIN
CHEMBL451930
Approved 2018
SIMEPREVIR SODIUM
CHEMBL3137358
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
BOCEPREVIR
CHEMBL218394
Approved 2011
OMACETAXINE MEPESUCCINATE
CHEMBL46286
Approved 2009
PRALATREXATE
CHEMBL1201746
Approved 2009
NILOTINIB
CHEMBL255863
Approved 2007
SORAFENIB
CHEMBL1336
Approved 2005
ATAZANAVIR
CHEMBL1163
Approved 2003
FULVESTRANT
CHEMBL1358
Approved 2002
IMATINIB
CHEMBL941
Approved 2001
TRIMETREXATE
CHEMBL119
Approved 1993
NICLOSAMIDE
CHEMBL1448
Approved 1982
FLUORESCEIN
CHEMBL1057
Approved 1976
DIGOXIN
CHEMBL1751
Approved 1975
DIPYRIDAMOLE
CHEMBL932
Approved 1961
HYDROXYCHLOROQUINE
CHEMBL1535
Approved 1955
METHOTREXATE
CHEMBL34259
Approved 1953
HEXACHLOROPHENE
CHEMBL496
Approved 1949
Assay Landscape

Assay Landscape

1,204
Total Assays
1,484
Tested Compounds
2
Assay Types
Functional — 1,203 assays, 1,484 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1,203 1,484 5.8
Toxicity — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine